<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00955981</url>
  </required_header>
  <id_info>
    <org_study_id>RDEA594-202</org_study_id>
    <nct_id>NCT00955981</nct_id>
  </id_info>
  <brief_title>Gout Dose Response Study</brief_title>
  <official_title>Randomized, Double-Blind, Multicenter, Placebo-Controlled, Safety and Efficacy Study of RDEA594 Versus Placebo in the Treatment of Hyperuricemia in Patients With Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardea Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the proportion of subjects whose serum urate (sUA) level is &lt; 6.0 mg/dL after 28
      days of dosing by treatment group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the proportion of subjects whose serum urate (sUA) level is &lt; 6.0 mg/dL after 28 days of dosing by treatment group.</measure>
    <time_frame>28 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the proportion of subjects whose sUA levels are &lt;6.0 mg/dL, &lt;5.0 mg/dL and &lt;4.0 mg/dL at each weekly study visit during the Double-Blind Period.</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the absolute and percent reduction from baseline in sUA levels at each weekly study visit.</measure>
    <time_frame>28 Days and through extension</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the percentage change in 24-hour urine urate level (excretion) from baseline to Day 28.</measure>
    <time_frame>28 Days and through extension</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the incidence of gout flares.</measure>
    <time_frame>28 Days and through extension</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of RDEA594 in subjects with gout.</measure>
    <time_frame>28 Days and through extension</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the proportion of subjects whose sUA level decreases to or is maintained at &lt;6.0 mg/dL in the Open-Label Extension Period.</measure>
    <time_frame>18 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>RDEA594 200 mg qd for 28 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RDEA594 200 mg, 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA594 200 mg qd for 7 days followed by 400 mg qd for 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDEA594 200 mg, 400 mg and 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDEA594 200 mg qd for 7 days followed by 400 mg qd for 7 days followed by 600 mg qd for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>RDEA594 matching placebo qd for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDEA594</intervention_name>
    <description>Uricosuric agent for the treatment of gout</description>
    <arm_group_label>RDEA594 200 mg qd for 28 days</arm_group_label>
    <arm_group_label>RDEA594 200 mg, 400 mg</arm_group_label>
    <arm_group_label>RDEA594 200 mg, 400 mg and 600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or post-menopausal or surgically sterile female.

          -  18 - 75 years of age.

          -  Hyperuricemic (i.e., screening sUA â‰¥8 mg/dL).

          -  Meets criteria for the diagnosis of gout as per the American Rheumatism Association
             (ARA) Criteria for the Classification of Acute Arthritis of Primary Gout.

          -  Willing and able to give informed consent and adhere to visit/protocol schedules
             (informed consent must be given before the first study procedure is performed).

          -  Subjects entering the optional Extension Period must have successfully completed the
             Double-Blind Treatment Period and Follow-up Period within approximately 4 months and
             must not have experienced any serious adverse events considered possibly related to
             study drug.

        Exclusion Criteria:

          -  Classified as an overproducer of urine urate (Cur &gt; 6.0 ml/min/1.73 m2 24- hour
             urine).

          -  Consumes more than 14 drinks of alcohol per week (e.g., 1 drink = 5 oz [150 ml] of
             wine, 12 oz [360 ml] of beer, or 1.5 oz [45 ml] of hard liquor).

          -  History or suspicion of drug abuse.

          -  Documented history of or suspicion of kidney stones.

          -  History of rheumatoid arthritis or other autoimmune disease.

          -  Confirmed (positive serology to HIV1 and HIV 2) or suspected HIV infection.

          -  Positive serology to HCV antibodies (Abs), and/or hepatitis B surface antigen (HBsAg).

          -  History of malignancy, except treated non-melanomatous skin cancer or cervical
             dysplasia.

          -  History of cardiac abnormalities, including abnormal and clinically relevant ECG
             changes such as bradycardia (sinus rate &lt;45 bpm), complete left bundle branch block
             (LBBB), second or third degree heart block, intraventricular conduction delay with QRS
             duration &gt;120 msec, symptomatic or asymptomatic arrhythmias with the exception of
             sinus arrhythmia, evidence of ventricular pre-excitation, frequent palpitations or
             syncopal episodes, heart failure, hypokalemia, family history of Long QT Syndrome,
             and/or family history of sudden death in an otherwise healthy individual between the
             ages of 1 and 30 years.

          -  Any condition predisposing them to QT prolongation including pathological Q-wave
             (defined as Q-wave &gt;40 msec or depth &gt; 0.4-0.5 mV).

          -  Any use of a concomitant medication that prolong the QT/QTc interval within the 14
             days prior to Baseline (Day 0)

          -  QT interval corrected for heart rate according to Fridericia (QTcF) &gt; 450 msec at
             Screening or pre-dose at Baseline (Day 0)

          -  Uncontrolled hypertension (above 150/95)

          -  Inadequate renal function

          -  Hemoglobin &lt; 10 g/dL (males) or &lt; 9 g/dL (females)

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 2.5 x upper limit
             of normal (ULN)

          -  Gamma glutamyl transferase (GGT) &gt; 3 x ULN

          -  Active peptic ulcer disease requiring treatment

          -  History of xanthinuria, active liver disease, or hepatic dysfunction.

          -  Requires therapy with any other urate-lowering medication, other than the study
             medication.

          -  Requires long-term use of salicylates; diuretics; azathioprine; mercaptopurine;
             theophylline; intravenous colchicine; cyclosporine; cyclophosphamide; pyrazinamide;
             sulfamethoxazole; or trimethoprim

          -  Taking medications known as enzyme inducers

          -  Receiving a strong or moderate inhibitor of CYP3A4 or a P-gp inhibitor within 1 month
             prior to study drug dosing

          -  Gout flare at screening that is resolved for less than one week prior to the first
             treatment with study medication (exclusive of chronic synovitis/ arthritis)

          -  Female of childbearing potential

          -  Received an investigational medication within 4 weeks prior to study medication
             administration

          -  Previously participated in a clinical study involving RDEA806 or RDEA594.

          -  Known hypersensitivity or allergy to RDEA594 or colchicine or any components in their
             formulations.

          -  Body mass index (BMI) &gt;40 kg/m2.

          -  Taking greater than 1000 mg/day of Vitamin C.

          -  Any other medical or psychological condition, which in the opinion of the Investigator
             and/or Medical Monitor, might create undue risk to the subject or interfere with the
             subject's ability to comply with the protocol requirements, or to complete the study.

          -  Inadequate renal function after completing the Double-Blind Treatment period prior to
             entering Extension Period.

          -  Requiring treatment with prohibited medications noted in exclusion criteria numbers
             20-23 after completing the Double-Blind Treatment Period prior to entering the
             Extension Period.

          -  Clinically relevant medical event as determined by the investigator in consultation
             with medical monitor prior to entering the Extension Period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vijay Hingorani, MD, PhD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Ardea Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovidv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <zip>1709</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <zip>V3K 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y8E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thornhill</city>
        <state>Ontario</state>
        <zip>L4J6W6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <zip>J7J 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bruntal</city>
        <zip>792 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <zip>140 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <zip>148 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tbilisi</city>
        <zip>0102</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goch</city>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nuremberg</city>
        <zip>90402</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <zip>20-607</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>61-289</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Radom</city>
        <zip>26-610</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <zip>53-025</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2009</study_first_submitted>
  <study_first_submitted_qc>August 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2009</study_first_posted>
  <disposition_first_submitted>January 7, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>February 5, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 7, 2014</disposition_first_posted>
  <last_update_submitted>February 5, 2014</last_update_submitted>
  <last_update_submitted_qc>February 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lesinurad</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 26, 2016</submitted>
    <returned>October 20, 2016</returned>
    <submitted>March 20, 2017</submitted>
    <returned>April 27, 2017</returned>
    <submitted>January 3, 2018</submitted>
    <returned>January 30, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

